Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | SLC9A1 | P19634 | 1/20 | 0.40 |
| ▸ | SLC9A2 | Q9UBY0 | 1/20 | 0.40 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.39 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.39 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.39 |
| ▸ | HTR3B | O95264 | 1/20 | 0.39 |
| ▸ | HTR1A | P08908 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | NCF1 | P14598 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.39 |
| ▸ | HTR1D | P28221 | 1/20 | 0.39 |
| ▸ | HTR1B | P28222 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9818549 | 0.79 | POLB (0.52) | NPC1MAPK1ALDH1A1CYP1A2SLC9A1 | |
| SCHEMBL860756 | 0.79 | NPC1 (0.50) | NPC1MAPK1ALDH1A1CYP1A2SLC9A1 | |
| SCHEMBL27894718 | 0.79 | NPC1 (0.50) | NPC1MAPK1ALDH1A1CYP1A2SLC9A1 | |
| SCHEMBL27916120 | 0.79 | NPC1 (0.50) | NPC1MAPK1ALDH1A1CYP1A2POLB | |
| SCHEMBL23400530 | 0.74 | NR3C2 (0.43) | MAPK1ALDH1A1NPBWR1HSD17B10TSHR | |
| SCHEMBL10790664 | 0.74 | POLB (0.41) | NPC1ALDH1A1POLBTSHRHPGD | |
| SCHEMBL14696701 | 0.74 | HSP90AA1 (0.54) | NOTUMPOLBHSD17B10MAPTMEN1 | |
| SCHEMBL29160308 | 0.71 | NPC1 (0.43) | NPC1MAPK1ALDH1A1CYP1A2POLB | |
| SCHEMBL28985365 | 0.71 | SIGMAR1 (0.48) | NPC1MAPK1ALDH1A1CYP1A2NOTUM | |
| SCHEMBL5277301 | 0.71 | TDP1 (0.52) | NPC1MAPK1ALDH1A1CYP1A2NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-8372807-B2 | Methods of modulating uric acid levels | ARDEA BIOSCIENCES, INC. (US) | 2013-02-12 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-31 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | ARDEA BIOSCIENCES INC. (US) | 2012-05-17 | — | — | US | disclosed |
| EP-2432774-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| EP-2432468-A2 | METHODS OF MODULATING URIC ACID LEVELS | Ardea Biosciences, Inc. (US) | 2012-03-28 | — | — | EP | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135536-A2 | METHODS OF MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
| WO-2010135530-A2 | COMPOUNDS, COMPOSITIONS AND METHODS FOR MODULATING URIC ACID LEVELS | ARDEA BIOSCIENCES, INC. (US) | 2010-11-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122780-A1 | Compounds, Compositions and Methods for Modulating Uric Acid Levels | XDH, PON1, RBP4 | NPC1 856/4885MAPK1 4331/4885ALDH1A1 188/4885 |
| US-20120135929-A1 | Methods Of Modulating Uric Acid Levels | XDH, PON1, OAT | NPC1 889/4885MAPK1 4577/4885ALDH1A1 167/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.